Base de dados : MEDLINE
Pesquisa : D02.033.800.813.480.500 [Categoria DeCS]
Referências encontradas : 3460 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 346 ir para página                         

  1 / 3460 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28692363
[Au] Autor:Patel P; Yau C; Kurian J
[Ad] Endereço:Cardiology Registrar and Clinical Research Fellow, Department of Cardiology, Leeds General Infirmary, Leeds LS1 3EX.
[Ti] Título:ST elevation myocardial infarction after coronary artery spasm with no clear trigger.
[So] Source:Br J Hosp Med (Lond);78(7):412-413, 2017 Jul 02.
[Is] ISSN:1750-8460
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Arritmias Cardíacas/etiologia
Vasoespasmo Coronário/complicações
Infarto do Miocárdio com Supradesnível do Segmento ST/etiologia
[Mh] Termos MeSH secundário: Anlodipino/uso terapêutico
Arritmias Cardíacas/terapia
Reanimação Cardiopulmonar
Angiografia Coronária
Vasoespasmo Coronário/diagnóstico
Vasoespasmo Coronário/tratamento farmacológico
Morte Súbita Cardíaca/prevenção & controle
Desfibriladores Implantáveis
Eletrocardiografia
Seres Humanos
Dinitrato de Isossorbida/análogos & derivados
Dinitrato de Isossorbida/uso terapêutico
Masculino
Meia-Idade
Nitroglicerina/uso terapêutico
Recidiva
Infarto do Miocárdio com Supradesnível do Segmento ST/diagnóstico
Vasodilatadores/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Vasodilator Agents); 1J444QC288 (Amlodipine); G59M7S0WS3 (Nitroglycerin); IA7306519N (Isosorbide Dinitrate); LX1OH63030 (isosorbide-5-mononitrate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170711
[St] Status:MEDLINE
[do] DOI:10.12968/hmed.2017.78.7.412


  2 / 3460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28288687
[Au] Autor:Lavon O; Avrahami A; Eisenkraft A
[Ad] Endereço:Clinical Pharmacology and Toxicology Unit, Carmel Medical Center, 7 Michal St., Haifa, 3436212, Israel. ophir.lavon@clalit.org.il.
[Ti] Título:Effectiveness of isosorbide dinitrate in cyanide poisoning as a function of the administration timing.
[So] Source:BMC Pharmacol Toxicol;18(1):13, 2017 Mar 14.
[Is] ISSN:2050-6511
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Better and safer antidotes against cyanide poisoning are needed. Prior study has shown a favorable effect of isosorbide dinitrate (ISDN) on the survival of cyanide-poisoned rabbits when administered as early as 1 min after poisoning. The aim of the current study was to further evaluate the efficacy of intravenous ISDN administered in clinically relevant timing for first responders. METHODS: A comparative animal study using 24 rabbits in 4 randomized study groups was performed. Animals were poisoned with intravenous potassium cyanide (1 mg/kg). Animals in Group 1 served as controls and received no treatment. Groups 2-4 animals were treated intravenously with ISDN (50 µg/kg) after poisoning; one group after 3 min, another group after 5 min and the last after 7 min. Animals were observed for 30 min after poisoning. The study endpoints included survival rate, clinical status, blood pressure, pulse per minute, blood lactate and pH. RESULTS: Five of 6 animals (83.3%) from every treatment group survived the whole observation period while all control untreated animals died. All the rabbits collapsed immediately after exposure, showing rapidly deteriorated vital signs with lactic metabolic acidosis (peak blood lactate levels of 18.1 to 19.0 mmol/L on average at 10 min post exposure). Vital signs, clinical scores, and blood gases of treated rabbits gradually improved. CONCLUSION: Poisoned rabbits showed improved short-term survival following the administration of ISDN up to 7 min after lethal cyanide poisoning of. We see a potential for ISDN as an antidote against cyanide poisoning.
[Mh] Termos MeSH primário: Dinitrato de Isossorbida/administração & dosagem
Envenenamento/tratamento farmacológico
Cianeto de Potássio/envenenamento
[Mh] Termos MeSH secundário: Administração Intravenosa
Animais
Esquema de Medicação
Envenenamento/sangue
Envenenamento/mortalidade
Cianeto de Potássio/sangue
Coelhos
Distribuição Aleatória
Taxa de Sobrevida/tendências
Resultado do Tratamento
Vasodilatadores/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Vasodilator Agents); IA7306519N (Isosorbide Dinitrate); MQD255M2ZO (Potassium Cyanide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170315
[St] Status:MEDLINE
[do] DOI:10.1186/s40360-017-0122-0


  3 / 3460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28100019
[Au] Autor:Villanueva C; Graupera I; Aracil C; Alvarado E; Miñana J; Puente Á; Hernandez-Gea V; Ardevol A; Pavel O; Colomo A; Concepción M; Poca M; Torras X; Reñe JM; Guarner C
[Ad] Endereço:Gastrointestinal Bleeding Unit, Department of Gastroenterology, Hospital de Sant Pau, Barcelona, Autonomous University, Barcelona, Spain.
[Ti] Título:A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.
[So] Source:Hepatology;65(5):1693-1707, 2017 May.
[Is] ISSN:1527-3350
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Monitoring the hemodynamic response of portal pressure (PP) to drug therapy accurately stratifies the risk of variceal rebleeding (VRB). We assessed whether guiding therapy with hepatic venous pressure gradient (HVPG) monitoring may improve survival by preventing VRB. Patients with cirrhosis with controlled variceal bleeding were randomized to an HVPG-guided therapy group (N = 84) or to a control group (N = 86). In both groups, HVPG and acute ß-blocker response were evaluated at baseline and HVPG measurements were repeated at 2-4 weeks to determine chronic response. In the HVPG-guided group, acute responders were treated with nadolol and acute nonresponders with nadolol+nitrates. Chronic nonresponders received nadolol+prazosin and had a third HVPG study. Ligation sessions were repeated until response was achieved. The control group was treated with nadolol+nitrates+ligation. Between-group baseline characteristics were similar. During long-term follow-up (median of 24 months), mortality was lower in the HVPG-guided therapy group than in the control group (29% vs. 43%; hazard ratio [HR] = 0.59; 95% confidence interval [CI] = 0.35-0.99). Rebleeding occurred in 19% versus 31% of patients, respectively (HR = 0.53; 95% CI = 0.29-0.98), and further decompensation of cirrhosis occurred in 52% versus 72% (HR = 0.68; 95% CI = 0.46-0.99). The survival probability was higher with HVPG-guided therapy than in controls, both in acute (HR = 0.59; 95% CI = 0.32-1.08) and chronic nonresponders (HR = 0.48; 95% CI = 0.23-0.99). HVPG-guided patients had a greater reduction of HVPG and a lower final value than controls (P < 0.05). CONCLUSION: HVPG monitoring, by stratifying risk and targeting therapy, improves the survival achieved with currently recommended treatment to prevent VRB using ß-blockers and ligation. HVPG-guided therapy achieved a greater reduction in PP, which may have contributed to reduce the risk of rebleeding and of further decompensation of cirrhosis, thus contributing to a better survival. (Hepatology 2017;65:1693-1707).
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos beta/administração & dosagem
Hemorragia Gastrointestinal/prevenção & controle
Hipertensão Portal/tratamento farmacológico
Cirrose Hepática/complicações
Pressão na Veia Porta
[Mh] Termos MeSH secundário: Idoso
Quimioterapia Combinada
Endoscopia Gastrointestinal
Feminino
Hemorragia Gastrointestinal/etiologia
Hemorragia Gastrointestinal/mortalidade
Seres Humanos
Hipertensão Portal/complicações
Dinitrato de Isossorbida/administração & dosagem
Dinitrato de Isossorbida/análogos & derivados
Cirrose Hepática/mortalidade
Masculino
Meia-Idade
Recidiva
Espanha/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); IA7306519N (Isosorbide Dinitrate); LX1OH63030 (isosorbide-5-mononitrate)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170523
[Lr] Data última revisão:
170523
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170119
[St] Status:MEDLINE
[do] DOI:10.1002/hep.29056


  4 / 3460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28057535
[Au] Autor:Flores Ramos JM; Devoize L; Descheemaeker A; Molat JL; Luccarini P; Dallel R
[Ad] Endereço:Université Clermont Auvergne, Inserm Neuro-Dol U1107, F-63000 Clermont-Ferrand, France.
[Ti] Título:The nitric oxide donor, isosorbide dinitrate, induces a cephalic cutaneous hypersensitivity, associated with sensitization of the medullary dorsal horn.
[So] Source:Neuroscience;344:157-166, 2017 Mar 06.
[Is] ISSN:1873-7544
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Nitric oxide donors are known to produce headache in healthy as well as migraine subjects, and to induce extracephalic cutaneous hypersensitivity in rodents. However, little is known on the effect of nitric oxide donors on cephalic cutaneous sensitivity. Combining behavioral, immunohistochemical, and in vivo electrophysiological approaches, this study investigated the effect of systemic administration of the nitric oxide donor, isosorbide dinitrate (ISDN), on cephalic and extracephalic cutaneous sensitivity and on neuronal activation within the medullary dorsal horn (MDH) in the rat. Systemic administration of ISDN increased selectively the first phase and interphase of the facial formalin test, but had no effect on the hindpaw formalin one. Monitoring neuronal activity within the MDH with phospho-ERK1/2 immunoreactivity revealed that ISDN alone did not activate MDH neurons, but significantly increased the number of formalin-evoked phospho-ERK1/2-immunoreactive cells in the ipsilateral, but not contralateral, MDH. Using in vivo electrophysiological unit recordings, we show that ISDN administration never affected the spontaneous activity of trigeminal wide dynamic range neurons, but, facilitated C-fiber-evoked responses in half the neurons tested. This research demonstrates that a nitric oxide donor, isosorbide dinitrate, induces selectively cephalic hyperalgesia that arises as a consequence of central sensitization in pain pathways that subserve meningeal nociception. This model better mimics the clinical condition and offers another possibility of studying the role of nitric oxide donor in the physiopathology of headache.
[Mh] Termos MeSH primário: Sensibilização do Sistema Nervoso Central/efeitos dos fármacos
Hiperalgesia/induzido quimicamente
Dinitrato de Isossorbida/toxicidade
Bulbo/efeitos dos fármacos
Doadores de Óxido Nítrico/toxicidade
Células do Corno Posterior/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Sensibilização do Sistema Nervoso Central/fisiologia
Modelos Animais de Doenças
Face/fisiopatologia
Formaldeído
Membro Posterior/fisiopatologia
Hiperalgesia/patologia
Hiperalgesia/fisiopatologia
Masculino
Bulbo/patologia
Bulbo/fisiopatologia
Transtornos de Enxaqueca/fisiopatologia
Medição da Dor
Células do Corno Posterior/patologia
Células do Corno Posterior/fisiologia
Distribuição Aleatória
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Nitric Oxide Donors); 1HG84L3525 (Formaldehyde); IA7306519N (Isosorbide Dinitrate)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170107
[St] Status:MEDLINE


  5 / 3460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27906702
[Au] Autor:Saito Y; Kitahara H; Nakayama T; Fujimoto Y; Kobayashi Y
[Ad] Endereço:Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
[Ti] Título:Diagnostic accuracy of intraluminal blood speckle intensity on intravascular ultrasound for physiological assessment of coronary artery stenosis.
[So] Source:Coron Artery Dis;28(2):145-150, 2017 Mar.
[Is] ISSN:1473-5830
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The difference in intraluminal intensity of blood speckle (IBS) on integrated backscatter intravascular ultrasound (IVUS) across the coronary stenosis was reportedly correlated with fractional flow reserve (FFR) in the left descending coronary artery. The aim of this study was to investigate the novel physiological assessment using IVUS in all coronary arteries. PATIENTS AND METHODS: Fifty-four patients with 57 coronary lesions underwent both FFR and IVUS. Intraluminal IBS was analyzed using integrated backscatter IVUS in cross-sections at the ostium and the distal site of the target vessel. ΔIBS was calculated as: (distal IBS)-(ostium IBS). RESULTS: Both ΔIBS (r=-0.50, P<0.01) and minimum lumen area (MLA) (r=0.55, P<0.01) showed significant correlations with FFR. There were significant correlations between FFR and ΔIBS in the right and left descending coronary arteries (r=-0.60, P=0.02, and r=-0.58, P<0.01), but not in the left circumflex (r=0.30, P=0.44). In receiver operating characteristic curve analyses, ΔIBS predicted FFR less than or equal to 0.80 (area under the curve=0.82, P<0.01, best cutoff value=6.78), as with MLA (area under the curve=0.83, P<0.01, best cutoff value=2.38). FFR progressively decreased in association with ΔIBS greater than or equal to 6.78 and MLA less than or equal to 2.38, and was the lowest when these were combined. CONCLUSION: ΔIBS was correlated with FFR in right and left descending coronary arteries. IVUS may assess coronary artery stenosis anatomically and physiologically.
[Mh] Termos MeSH primário: Estenose Coronária/diagnóstico por imagem
Vasos Coronários/diagnóstico por imagem
Ultrassonografia de Intervenção
[Mh] Termos MeSH secundário: Idoso
Área Sob a Curva
Cateterismo Cardíaco
Angiografia Coronária
Estenose Coronária/fisiopatologia
Vasos Coronários/fisiopatologia
Feminino
Reserva Fracionada de Fluxo Miocárdico
Seres Humanos
Dinitrato de Isossorbida/administração & dosagem
Masculino
Meia-Idade
Valor Preditivo dos Testes
Curva ROC
Reprodutibilidade dos Testes
Estudos Retrospectivos
Espalhamento de Radiação
Índice de Gravidade de Doença
Vasodilatadores/administração & dosagem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Vasodilator Agents); IA7306519N (Isosorbide Dinitrate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161202
[St] Status:MEDLINE
[do] DOI:10.1097/MCA.0000000000000457


  6 / 3460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27809622
[Au] Autor:Abdel Razik M; El-Berry S; El-Nezamy A; Saad A; Abdel Wahab A
[Ad] Endereço:a Department of Obstetrics and Gynecology, Benha Faculty of Medicine , Benha University , Benha , Egypt.
[Ti] Título:Nitric oxide donors increase the pregnancy rate in patients with unexplained infertility undergoing clomiphene citrate stimulation and intrauterine insemination: a randomized controlled pilot study.
[So] Source:Gynecol Endocrinol;33(3):199-202, 2017 Mar.
[Is] ISSN:1473-0766
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This study evaluated the effects of nitric oxide donor's treatment on the pregnancy rate and uterine blood flow in patients with unexplained infertility undergoing clomiphene citrate stimulation and intrauterine insemination. A total of 120 patients were randomly allocated to a control group who received 100 mg clomiphene citrate daily from day 5 to 9 of cycle plus placebo vaginal tablets, and a study group received clomiphene citrate plus isosorbide mononitrate 10 mg vaginal tablets. Vaginal ultrasound was done before treatment and every other day starting from day 12 of cycle to count mature follicles and ovulation was triggered by IM injection of 10 000 IU hCG when one follicle measured 18 ≥ mm followed by intrauterine insemination after 36 h. The endometrial thickness, uterine arteries resistance and pulsation indices, and endometrial vascular flow and vascular flow indices were measured before treatment and at day of hCG injection. Results were analyzed after one cycle treatment using the Mean ± SD, the Student t test and the Fisher Exact test. Significant result was considered at p values <0.05. The study group had significant higher pregnancy rate/cycle, higher endometrial and lower uterine artery blood flow indices (p < 0.05).
[Mh] Termos MeSH primário: Infertilidade Feminina/terapia
Inseminação Artificial
Dinitrato de Isossorbida/análogos & derivados
Doadores de Óxido Nítrico/uso terapêutico
Indução da Ovulação
Artéria Uterina/efeitos dos fármacos
Vasodilatadores/uso terapêutico
[Mh] Termos MeSH secundário: Administração Intravaginal
Adulto
Clomifeno/uso terapêutico
Egito
Endométrio/irrigação sanguínea
Endométrio/efeitos dos fármacos
Feminino
Fármacos para a Fertilidade Feminina/uso terapêutico
Fase Folicular/efeitos dos fármacos
Hospitais Universitários
Seres Humanos
Infertilidade Feminina/fisiopatologia
Dinitrato de Isossorbida/administração & dosagem
Dinitrato de Isossorbida/uso terapêutico
Doadores de Óxido Nítrico/administração & dosagem
Projetos Piloto
Gravidez
Taxa de Gravidez
Fluxo Sanguíneo Regional/efeitos dos fármacos
Comprimidos
Artéria Uterina/fisiopatologia
Resistência Vascular/efeitos dos fármacos
Vasodilatadores/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Fertility Agents, Female); 0 (Nitric Oxide Donors); 0 (Tablets); 0 (Vasodilator Agents); 1HRS458QU2 (Clomiphene); IA7306519N (Isosorbide Dinitrate); LX1OH63030 (isosorbide-5-mononitrate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161105
[St] Status:MEDLINE
[do] DOI:10.1080/09513590.2016.1240775


  7 / 3460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27720852
[Au] Autor:Misra D; Peloquin C; Kiel DP; Neogi T; Lu N; Zhang Y
[Ad] Endereço:Boston University School of Medicine, Mass. Electronic address: demisra@bu.edu.
[Ti] Título:Intermittent Nitrate Use and Risk of Hip Fracture.
[So] Source:Am J Med;130(2):229.e15-229.e20, 2017 Feb.
[Is] ISSN:1555-7162
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Nitrates, commonly used antianginal medications, also have a beneficial effect on bone remodeling and bone density, particularly with intermittent use. However, their effect on fracture risk is not clear. We examined the relation of short-acting nitrate use (proxy for intermittent use) with the risk of hip fracture in a large cohort of older adults with ischemic heart disease. METHODS: Participants aged 60 years or more with ischemic heart disease and without a history of hip fracture from The Health Improvement Network, an electronic medical records database in the United Kingdom, were included. The association of incident (new) use of short-acting nitrate formulations (nitroglycerin sublingual/spray/ointment or isosorbide dinitrate injection/sprays) with incident (new-onset) hip fracture risk was examined by plotting Kaplan-Maier curves and calculating hazard ratios using Cox proportional hazards regression models. Competing risk by death was analyzed in separate analyses. RESULTS: Among 14,451 pairs of matched nitrate users and nonusers (mean age, 72 ± 7.6 years, 41% women for each cohort), 573 fractures occurred during follow-up (257 nitrate users; 316 nonusers). Hip fracture risk was 33% lower among short-acting nitrate users compared with nonusers (hazard ratio, 0.67; 95% confidence interval, 0.53-0.85; P = .0008). Competing risk analysis by death did not change effect estimates. CONCLUSIONS: In this large population-based cohort of older adults with ischemic heart disease, we found a significant reduction in hip fracture risk with the use of short-acting nitrates (intermittent use). Future studies are warranted given the potential for nitrates to be potent, inexpensive, and readily available antiosteoporotic agents.
[Mh] Termos MeSH primário: Fraturas do Quadril/induzido quimicamente
Dinitrato de Isossorbida/efeitos adversos
Nitroglicerina/efeitos adversos
Vasodilatadores/efeitos adversos
[Mh] Termos MeSH secundário: Idoso
Angina Estável/tratamento farmacológico
Feminino
Seres Humanos
Dinitrato de Isossorbida/uso terapêutico
Estimativa de Kaplan-Meier
Masculino
Isquemia Miocárdica/tratamento farmacológico
Nitroglicerina/uso terapêutico
Modelos de Riscos Proporcionais
Vasodilatadores/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Vasodilator Agents); G59M7S0WS3 (Nitroglycerin); IA7306519N (Isosorbide Dinitrate)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170508
[Lr] Data última revisão:
170508
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161011
[St] Status:MEDLINE


  8 / 3460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26924839
[Au] Autor:Hansen EK; Olesen J
[Ad] Endereço:Danish Headache Centre and Department of Neurology, University of Copenhagen, Rigshospitalet Glostrup, Denmark.
[Ti] Título:Towards a pragmatic human migraine model for drug testing: 2. Isosorbide-5-mononitrate in healthy individuals.
[So] Source:Cephalalgia;37(1):11-19, 2017 Jan.
[Is] ISSN:1468-2982
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background A model for the testing of novel anti-migraine drugs should preferably use healthy volunteers for ease of recruiting. Isosorbide-5-mononitrate (5-ISMN) provokes headache in healthy volunteers with some migraine features such as pulsating pain quality and aggravation by physical activity. Therefore, this headache might respond to sumatriptan, a requirement for validation of any model. The hypothesis of the present study was that sumatriptan is effective in 5-ISMN-induced headache in healthy individuals. Methods In a double-blind, randomised, crossover design, 30 healthy volunteers of both sexes received 5-ISMN 60 mg on two separate days, each day followed by oral self-administered placebo or sumatriptan 50 mg. Headache response and accompanying symptoms were registered in a questionnaire by the participants themselves. Results 5-ISMN induced a reproducible headache in all 30 participants. The headache had several migraine-like features in all participants and 20 individuals developed a migraine-like attack. Median peak headache score was 5 on both experimental days ( p = 1.00). There was no reduction, but instead an increase in headache intensity 2 hours after sumatriptan ( p = 0.003). Difference in area under the headache score curve (AUC) 0-4 hours between sumatriptan and placebo was not significant ( p = 0.30). Conclusion 5-ISMN is a very powerful inducer of migraine-like headache in healthy individuals but the headache does not respond to sumatriptan. The model is not useful for future drug testing.
[Mh] Termos MeSH primário: Dinitrato de Isossorbida/análogos & derivados
Transtornos de Enxaqueca/induzido quimicamente
Transtornos de Enxaqueca/tratamento farmacológico
Agonistas de Receptores 5-HT1 de Serotonina/uso terapêutico
Sumatriptana/uso terapêutico
Vasodilatadores/toxicidade
[Mh] Termos MeSH secundário: Adulto
Estudos Cross-Over
Método Duplo-Cego
Feminino
Voluntários Saudáveis
Seres Humanos
Dinitrato de Isossorbida/toxicidade
Masculino
Meia-Idade
Modelos Biológicos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Serotonin 5-HT1 Receptor Agonists); 0 (Vasodilator Agents); 8R78F6L9VO (Sumatriptan); IA7306519N (Isosorbide Dinitrate); LX1OH63030 (isosorbide-5-mononitrate)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170310
[Lr] Data última revisão:
170310
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160301
[St] Status:MEDLINE
[do] DOI:10.1177/0333102416636095


  9 / 3460 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27708003
[Au] Autor:Raj L; Adhyaru B
[Ad] Endereço:Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
[Ti] Título:An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF).
[So] Source:Postgrad Med J;92(1094):726-734, 2016 Dec.
[Is] ISSN:1469-0756
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:An estimated 5.1 million Americans have chronic heart failure and this is expected to increase 25% by 2030. Heart failure is a clinical syndrome that evolves from either functional or structural changes to the ventricles that lead to filling or ejection abnormalities. Thus far, pharmacotherapy has been show to be beneficial in patients only with reduced ejection fraction; however, new therapies have been developed in hopes of reducing the burden of heart failure. In this review, we will discuss current pharmacotherapies recommended in American College of Cardiology/American Heart Association guidelines, the evidence behind these recommendations as well as new and emerging therapies that have been developed.
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos beta/uso terapêutico
Antagonistas de Receptores de Angiotensina/uso terapêutico
Inibidores da Enzima Conversora de Angiotensina/uso terapêutico
Fármacos Cardiovasculares/uso terapêutico
Diuréticos/uso terapêutico
Insuficiência Cardíaca/tratamento farmacológico
Antagonistas de Receptores de Mineralocorticoides/uso terapêutico
Volume Sistólico
[Mh] Termos MeSH secundário: American Heart Association
Amidas/uso terapêutico
Aminobutiratos/uso terapêutico
Anticoagulantes/uso terapêutico
Anti-Hipertensivos/uso terapêutico
Fator Natriurético Atrial/uso terapêutico
Benzazepinas/uso terapêutico
Bloqueadores dos Canais de Cálcio/uso terapêutico
Cardiologia
Cardiotônicos/uso terapêutico
Digoxina/uso terapêutico
Combinação de Medicamentos
Eritropoetina/uso terapêutico
Medicina Baseada em Evidências
Fumaratos/uso terapêutico
Insuficiência Cardíaca/fisiopatologia
Hematínicos/uso terapêutico
Seres Humanos
Hidralazina/uso terapêutico
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Ferro/uso terapêutico
Dinitrato de Isossorbida/uso terapêutico
Fragmentos de Peptídeos/uso terapêutico
Inibidores da Agregação de Plaquetas/uso terapêutico
Guias de Prática Clínica como Assunto
Sociedades Médicas
Tetrazóis/uso terapêutico
Estados Unidos
Vasodilatadores/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); 0 (Amides); 0 (Aminobutyrates); 0 (Angiotensin Receptor Antagonists); 0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Anticoagulants); 0 (Antihypertensive Agents); 0 (Benzazepines); 0 (Calcium Channel Blockers); 0 (Cardiotonic Agents); 0 (Cardiovascular Agents); 0 (Diuretics); 0 (Drug Combinations); 0 (Fumarates); 0 (Hematinics); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (LCZ 696); 0 (Mineralocorticoid Receptor Antagonists); 0 (Peptide Fragments); 0 (Platelet Aggregation Inhibitors); 0 (Tetrazoles); 0 (Vasodilator Agents); 0 (isosorbide-hydralazine combination); 11096-26-7 (Erythropoietin); 26NAK24LS8 (Hydralazine); 3H48L0LPZQ (ivabradine); 502FWN4Q32 (aliskiren); 73K4184T59 (Digoxin); 740Y5J48Z8 (Ularitide); 85637-73-6 (Atrial Natriuretic Factor); E1UOL152H7 (Iron); IA7306519N (Isosorbide Dinitrate)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170322
[Lr] Data última revisão:
170322
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161007
[St] Status:MEDLINE
[do] DOI:10.1136/postgradmedj-2016-134378


  10 / 3460 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27494724
[Au] Autor:Gohbara M; Endo T; Kimura K
[Ad] Endereço:Division of Cardiology, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan. Electronic address: gocchi3@hotmail.com.
[Ti] Título:A case of initial rhythm of pulseless electrical activity caused by vasospastic angina.
[So] Source:Int J Cardiol;222:130-2, 2016 Nov 01.
[Is] ISSN:1874-1754
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Reanimação Cardiopulmonar/métodos
Vasoespasmo Coronário
Di-Hidropiridinas/administração & dosagem
Parada Cardíaca
Dinitrato de Isossorbida/análogos & derivados
[Mh] Termos MeSH secundário: Angiocardiografia/métodos
Angiografia Coronária/métodos
Vasoespasmo Coronário/complicações
Vasoespasmo Coronário/diagnóstico
Vasoespasmo Coronário/tratamento farmacológico
Vasoespasmo Coronário/fisiopatologia
Técnicas Eletrofisiológicas Cardíacas/métodos
Parada Cardíaca/diagnóstico
Parada Cardíaca/etiologia
Parada Cardíaca/terapia
Seres Humanos
Dinitrato de Isossorbida/administração & dosagem
Masculino
Meia-Idade
Resultado do Tratamento
Vasodilatadores/administração & dosagem
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Dihydropyridines); 0 (Vasodilator Agents); 4G9T91JS7E (benidipine); IA7306519N (Isosorbide Dinitrate); LX1OH63030 (isosorbide-5-mononitrate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160806
[St] Status:MEDLINE



página 1 de 346 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde